Cancer therapy: back to metabolism

Cancer Biol Ther. 2006 Aug;5(8):986-7. doi: 10.4161/cbt.5.8.3314. Epub 2006 Aug 23.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / pharmacology
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / pathology
  • Cell Cycle / drug effects*
  • Fatty Acid Synthases / antagonists & inhibitors*
  • Fatty Acids / metabolism*
  • Humans
  • Liver Neoplasms / genetics
  • Liver Neoplasms / metabolism*
  • Liver Neoplasms / pathology
  • Tumor Suppressor Protein p53 / antagonists & inhibitors
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • fas Receptor / antagonists & inhibitors
  • fas Receptor / metabolism
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / genetics
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
  • Fatty Acids
  • Tumor Suppressor Protein p53
  • fas Receptor
  • Fatty Acid Synthases
  • p38 Mitogen-Activated Protein Kinases
  • 4-Butyrolactone